Faeth Therapeutics awarded one-time performance-based stock options to CEO Anand Parikh, General Counsel Christopher Gerry and SVP Finance Josiah Craver under its 2026 Equity Incentive Plan.
| IndividualAnand ParikhChristopher GerryJosiah Craver | RoleChief Executive OfficerGeneral Counsel and SecretarySenior Vice President, Finance | Type of ChangeAwarded performance-based stock optionAwarded performance-based stock optionAwarded performance-based stock option | Effective DateJuly 21, 2026July 21, 2026July 21, 2026 | ReasonOne-time supplemental grant approved by Board upon Compensation Committee recommendationOne-time supplemental grant approved by Board upon Compensation Committee recommendationOne-time supplemental grant approved by Board upon Compensation Committee recommendation | Replacement InfoNot disclosedNot disclosedNot disclosed | Background DetailsGranted 398,018 Performance Options; exercise price = Nasdaq closing price on grant; vesting upon meeting $70 stock-price hurdle and one-year serviceGranted 84,766 Performance Options; exercise price = Nasdaq closing price on grant; vesting upon meeting $70 stock-price hurdle and one-year service; Board determined in June 2026 he is not an "executive officer" under Rule 3b-7Granted 30,824 Performance Options; exercise price = Nasdaq closing price on grant; vesting upon meeting $70 stock-price hurdle and one-year service; Board determined in June 2026 he is not an "executive officer" under Rule 3b-7 | Board/Committee Role ChangesNot disclosedNot disclosedNot disclosed |
Original SEC Filing:
This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.